TY - JOUR
T1 - Current and emerging pharmacotherapeutic options for smoking cessation
AU - Carson, Kristin V.
AU - Brinn, Malcolm P.
AU - Robertson, Thomas A.
AU - To-A-Nan, Rachada
AU - Esterman, Adrian J.
AU - Peters, Matthew
AU - Smith, Brian J.
PY - 2013
Y1 - 2013
N2 - Tobacco smoking remains the single most preventable cause of morbidity and mortality in developed countries and poses a significant threat across developing countries where tobacco use prevalence is increasing. Nicotine dependence is a chronic disease often requiring multiple attempts to quit; repeated interventions with pharmacotherapeutic aids have become more popular as part of cessation therapies. First-line medications of known efficacy in the general population include varenicline tartrate, bupropion hydrochloride, nicotine replacement therapy products, or a combination thereof. However, less is known about the use of these products in marginalized groups such as the indigenous, those with mental illnesses, youth, and pregnant or breastfeeding women. Despite the efficacy and safety of these first line pharmacotherapies, many smokers continue to relapse and alternative pharmacotherapies and cessation options are required. Thus, the aim of this review is to summarize the existing and developing pharmacotherapeutic and other options for smoking cessation, to identify gaps in current clinical practice, and to provide recommendations for future evaluations and research.
AB - Tobacco smoking remains the single most preventable cause of morbidity and mortality in developed countries and poses a significant threat across developing countries where tobacco use prevalence is increasing. Nicotine dependence is a chronic disease often requiring multiple attempts to quit; repeated interventions with pharmacotherapeutic aids have become more popular as part of cessation therapies. First-line medications of known efficacy in the general population include varenicline tartrate, bupropion hydrochloride, nicotine replacement therapy products, or a combination thereof. However, less is known about the use of these products in marginalized groups such as the indigenous, those with mental illnesses, youth, and pregnant or breastfeeding women. Despite the efficacy and safety of these first line pharmacotherapies, many smokers continue to relapse and alternative pharmacotherapies and cessation options are required. Thus, the aim of this review is to summarize the existing and developing pharmacotherapeutic and other options for smoking cessation, to identify gaps in current clinical practice, and to provide recommendations for future evaluations and research.
UR - http://www.scopus.com/inward/record.url?scp=84878406866&partnerID=8YFLogxK
U2 - 10.4137/SART.S8108
DO - 10.4137/SART.S8108
M3 - Review article
C2 - 23772176
AN - SCOPUS:84878406866
VL - 7
SP - 85
EP - 105
JO - Substance Abuse: Research and Treatment
JF - Substance Abuse: Research and Treatment
SN - 1178-2218
ER -